Urologic Oncology: Seminars and Original Investigations This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Editorial Board
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - October 30, 2018 Category: Urology & Nephrology Source Type: research

Table of Contents
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - October 30, 2018 Category: Urology & Nephrology Source Type: research

Cover 3
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - October 30, 2018 Category: Urology & Nephrology Source Type: research

The expression profile of p14, p53 and p21 in tumour cells is associated with disease-specific survival and the outcome of postoperative chemotherapy treatment in muscle-invasive bladder cancer
Patients with muscle-invasive urinary bladder cancer (MIBC) treated with cystectomy have a high risk of recurrence and cancer-related death despite aggressive treatment. Recurrence-free survival after radical cystectomy (RC) and lymph node (LN) dissection at five years ranges from 58% to 62% [1,2]. Clinical and pathological variables such as T-category, tumour grade, lymphovascular invasion (LVI), and number of LN metastases are used as prognostic indicators in assessment of patients with urinary bladder cancer (UBC) [3 –5]. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - October 24, 2018 Category: Urology & Nephrology Authors: Firas Aljabery, Ivan Shabo, Oliver Gimm, Staffan Jahnson, Hans Olsson Tags: Original article Source Type: research

Post-translational modifications in bladder cancer: Expanding the tumor target repertoire
Bladder cancer (BCa) is the second most common urological malignancy after prostate cancer and a major cause of morbidity and death with enormous health-related cost. Approximately, 75% of newly diagnosed BCa patients have non-muscle invasive bladder cancer (NMIBC). Of this group, 70% of patients experience post-treatment recurrence that requires lifelong monitoring and up to 25% progress to more advanced disease [1,2]. In contrast to NMIBC, muscle-invasive bladder cancer (MIBC) is highly metastatic with a 5-year survival rate of approximately 50% in patients undergoing treatment [3]. (Source: Urologic Oncology: Seminars a...
Source: Urologic Oncology: Seminars and Original Investigations - October 17, 2018 Category: Urology & Nephrology Authors: Htoo Zarni Oo, Roland Seiler, Peter C. Black, Mads Daugaard Tags: Seminars article Source Type: research

Heat shock proteins 60 and 70 are associated with long-term outcome of T1-stage high-grade urothelial tumors of the bladder treated with intravesical Bacillus Calmette-Gu érin immunotherapy
Bladder cancer is the ninth most frequently diagnosed cancer worldwide, with the highest incidence rates observed in North America and Europe [1]. At the time of diagnosis, approximately 75% of bladder cancers are nonmuscle invasive, 50% of which are high-grade [2,3]. Progression rates of nonmuscle invasive bladder cancer (NMIBC) range from 10% to 30% at 5years [3]. Intravesical Bacillus Calmette-Gu érin (BCG) immunotherapy is the mainstay of treatment for high-grade tumors; however, patients who fail BCG immunotherapy are at the highest risk of disease progression and may benefit from early radical cystectomy [4]. (Sourc...
Source: Urologic Oncology: Seminars and Original Investigations - October 15, 2018 Category: Urology & Nephrology Authors: Roy Mano, Sofia Zilber, Renzo G. Di Natale, Daniel Kedar, David A. Lifshitz, Ofer Yossepowitch, Jack Baniel, David Margel Tags: Original article Source Type: research

Semen AMACR protein as a novel method for detecting prostate cancer
This study explores the detection of semen AMACR protein in men with and without CaP. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - October 15, 2018 Category: Urology & Nephrology Authors: Tyler Etheridge, Jane Straus, Mark A. Ritter, David F. Jarrard, Wei Huang Tags: Original article Source Type: research

Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma
Carbonic anhydrases constitute a large family of transmembrane zinc metalloenzymes catalyzing hydration of carbonic dioxide to form bicarbonate and hydrogen ions (reviewed in [1]). Carbonic anhydrases play a pivotal role in tissue pH homeostasis [2]. They have further been shown to play a role in the regulation of cell adhesion [3], and they are required for cellular growth and survival under normoxia and hypoxia [4,5]. It is probably because of this later function, that carbonic anhydrase 9 (CAIX) is often deregulated in cancer. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - October 12, 2018 Category: Urology & Nephrology Authors: Franziska B üscheck, Christoph Fraune, Ronald Simon, Martina Kluth, Claudia Hube-Magg, Christina Möller-Koop, Navid Shadanpour, Clemens Bannenberg, Christian Eichelberg, Doris Höflmayer, Till Clauditz, Corinna Wittmer, Waldemar Wilczak, Guido Sauter, M Tags: Original article Source Type: research

Zonal mapping of sentinel lymph nodes in penile cancer patients using fused SPECT/CT imaging and lymphoscintigraphy
Squamous cell carcinoma of the penis is rare with an incidence of 0.3 to 1.6 new cases per 100,000 males per year in Western Europe and North America [1,2]. Anatomical and observational studies have demonstrated that the lymphatic drainage from the penis initially travels to the superficial inguinal lymph nodes followed by the deep inguinal lymph nodes before spreading to the pelvic lymph nodes [3,4]. Previous studies have also shown that the most important prognostic indicator in patients diagnosed with penile cancer is the presence of metastatic inguinal lymph node disease [5,6]. (Source: Urologic Oncology: Seminars and ...
Source: Urologic Oncology: Seminars and Original Investigations - October 12, 2018 Category: Urology & Nephrology Authors: Savvas Omorphos, Zia Saad, Alex Kirkham, Raj Nigam, Peter Malone, Jamshed Bomanji, Asif Muneer Tags: Original article Source Type: research

A urinary microRNA (miR) signature for diagnosis of bladder cancer
Bladder cancer is the ninth most common malignancy worldwide, with an estimated 429,000 new cases diagnosed annually. At the time of diagnosis, the majority of tumors are well differentiated and do not invade the bladder's detrusor muscle, so called low-grade non-muscle invasive bladder cancer (LGNMIBC). Despite aggressive treatment by transurethral resection and intravesical instillations, LGNMIBC recurs in approximately 50% of patients. However, these tumors rarely progress to a higher grade or stage and have therefore an excellent prognosis [1]. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - October 12, 2018 Category: Urology & Nephrology Authors: Sebastian L. Hofbauer, Michela de Martino, Ilaria Lucca, Andrea Haitel, Martin Susani, Shahrokh F. Shariat, Tobias Klatte Tags: Original article Source Type: research

Prostate cancer in transgender women
As society at large begins to better recognize and understand gender dysphoria and the social and psychological issues surrounding transgender patients, we anticipate that more transgender individuals will feel comfortable in seeking urologic care. Urologists need to be better educated about social, behavioral, physiological, and anatomical issues that face transgender patients. Though estimation is difficult, attempts have been made to quantify the number of transgender persons currently in the United States. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - October 12, 2018 Category: Urology & Nephrology Authors: Matthew D. Ingham, Richard J. Lee, Dhara MacDermed, Aria F. Olumi Tags: Review Article Source Type: research

What kind of patients with castration-na ïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis
The field of systemic therapies for late-stage prostate cancer has remarkably progressed in the past 10 years; however, patients with metastatic castration-na ïve prostate cancer (mCNPC, M1) had limited improvement in overall survival (OS) [1,2]. In this context, some experts argue that optimal sequential or early combination therapy with novel agents showing clear survival benefit in metastatic castration-resistant prostate cancer (mCRPC) have the poten tial to delay disease progression and bring greater opportunity to improve survival in patients with de novo mCNPC. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - October 10, 2018 Category: Urology & Nephrology Authors: Guangxi Sun, Xingming Zhang, Junru Chen, Banghua Liao, Zhenhua Liu, Jinge Zhao, Allen C. Gao, Yaojing Yang, Kunpeng Shu, Jiandong Liu, Peng Zhao, Pengfei Shen, Hao Zeng Source Type: research

The addition of chemotherapy in the definitive management of high risk prostate cancer
In attempt to improve disease control outcomes for high-risk prostate cancer, numerous clinical trials have tested the addition of chemotherapy (CTX) —either adjuvant or neoadjuvant—to definitive local therapy, either radical prostatectomy (RP) or radiation therapy (RT). (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - October 8, 2018 Category: Urology & Nephrology Authors: Matthew J. Ferris, Yuan Liu, Jingning Ao, Jim Zhong, Mustafa Abugideiri, Theresa W. Gillespie, Bradley C. Carthon, Mehmet A. Bilen, Omer Kucuk, Ashesh B. Jani Tags: Review article Source Type: research

Focal therapy in localised prostate cancer: Real-world urological perspective explored in a cross-sectional European survey
Modern surgical oncology is increasingly moving towards tissue-preserving strategies over radical approaches in the vast majority of malignancies, provided that such approaches are technically feasible and oncologically effective [1 –4]. Whilst there is some interest in such a concept for prostate cancer (PCa), the prostate does still remain the last solid organ for which whole-gland treatments are carried out as standard of care. It is indeed an exception to treat in the same manner men harbouring measurable disease ranging from high volume low-risk to high-risk disease. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - October 6, 2018 Category: Urology & Nephrology Authors: Giancarlo Marra, Guillaume Ploussard, Piet Ost, Pieter J.L. De Visschere, Alberto Briganti, Giorgio Gandaglia, Derya Tilki, Christian I. Surcel, Igor Tsaur, Roderick C.N. Van Den Bergh, Alexander Kretschmer, Hendrik Borgmann, Paolo Gontero, Hashim U. Ahme Tags: Original article Source Type: research

Current controversies and developments on the role of lymphadenectomy for penile cancer
Penile squamous cell carcinoma is a rare cancer in men. The main prognosticators of survival for penile cancer patients remain the presence and the extent of lymph node metastasis. While radical inguinal lymphadenectomy has been the cornerstone of regional lymph node management for many years, it is still associated with significant morbidity and psychological distress. Recent developments in penile squamous cell carcinoma management have been met with some controversy in the urologic oncology community. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - October 6, 2018 Category: Urology & Nephrology Authors: Mounsif Azizi, Juan Chipollini, Charles C. Peyton, Salim K. Cheriyan, Philippe E. Spiess Tags: Seminars article Source Type: research